Contact Us

Press release

(May 13, 2024) - The collaborative center will help to lower barriers to RNA innovation and discovery

 

San Diego, U.S. (May 13, 2024) – TriLink BioTechnologies (TriLink®), a Maravai™ LifeSciences company (NASDAQ: MRVI) and global provider of life science reagents and services, is collaborating with the Johns Hopkins University to accelerate transformational research in RNA therapeutics and discovery.  A new center within the Johns Hopkins Whiting School of Engineering will accelerate research and the...

(April 30, 2024) - Lonza customers can now access TriLink’s CleanCap® mRNA capping technology for non-commercial use, enabling further development of critical mRNA therapeutics

San Diego, U.S. (April 30, 2024) – TriLink BioTechnologies (TriLink®), a Maravai™ LifeSciences company (NASDAQ: MRVI) and global provider of life science reagents and services, has signed a non-exclusive License and Supply Agreement with Lonza, a global development and manufacturing partner to the pharma, biote...

(April 18, 2024) - cGMP Facility Streamlines Clinical & Commercial mRNA Drug Substance Development; Built by mRNA & Industry Experts to Meet Demand for mRNA-based Medicine

SAN DIEGO (April 18, 2024) – TriLink BioTechnologies (TriLink®), a Maravai LifeSciences company (NASDAQ: MRVI) and global provider of life science reagents and services, has announced the grand opening of its new cG...

(February 21, 2024) - TriLink’s CleanCap® Capping Technology is Patented Globally & TriLink is the Sole Authorized Manufacturer of CleanCap® Capping Analogs 

SAN DIEGO (February 21, 2024)TriLink B...

(February 5, 2024) - TriLink CleanCap® mRNA capping technology is now accessible to Fujifilm customers for non-commercial use

TOKYO, JAPAN (February 5, 2024) – TriLink BioTechnologies (TriLink®), a Maravai™ LifeSciences company (NASDAQ: MRVI) and global provider of life science reagents and services, and FUJIFILM Toyama Chemical, a Japanese provider of synthetic mRNA contract development and manufacturing services, have entered into a non-exclusive License and Supply Agreement for TriLink’s CleanCap® mRNA capping technology.

 

Aligned to the terms ...

(November 2, 2023) - Centralized hub for advanced testing of nucleic acids to simplify mRNA drug substance testing, accelerating critical therapeutic development

SAN DIEGO (November 2, 2023)TriLink BioTechnologies (TriLink), a Maravai LifeSciences company (NASDAQ: MRVI) and global provider of life science reagents and services, has launched its Analytical Sciences Center of Excellence (ASCE) hub. Expanding its comprehensive suite of analytical t...

(November 1, 2023) - SAN DIEGO –TriLink BioTechnologies (TriLink®), a Maravai LifeSciences company (NASDAQ: MRVI) and a recognized leader in the production of high-quality nucleic acid-based products, today renews a multi-year supply agreement with Intellia Therapeutics, a pioneering genome editing company.

This agreement ensures the consistent provis...

(May 24, 2023) - GMP Facility Expected to Simplify the mRNA Drug Substance Development Process; Slated to Welcome Customers in Early 2024

SAN DIEGO (May 24, 2023)TriLink BioTechnologies (TriLink®), a Maravai LifeSciences company (NASDAQ: MRVI) and global provider of life science reagents and services, has announced the expansion of its mRNA m...

(May 9, 2023) - Newest cap analog product improves mRNA potency with greater protein expression, offers time and cost savings, and streamlines manufacturing to drive critical therapeutic and vaccine development 

SAN DIEGO (May 9, 2023)TriLink BioTechnologies (TriLink), a Maravai LifeSciences company (NASDAQ:...

(September 13, 2022) - TriLink now offers GMP-grade N1-Methyl-Pseudouridine-5’-Triphosphate, a critical raw material for mRNA manufacturing, allowing researchers to accelerate their drug discovery and development timelines and US-source their supply chain.

SAN DIEGO - TriLink BioTechnologies (“TriLink”), a Maravai LifeSciences company (NASDAQ: MRVI) and global provider of life science reagents and services, has expanded its GMP-grade product offering to include N1-Methyl-Pseudouridine-5’-Triphosphate (N1meΨTP), a modified nucleoside-triphosph...

(July 6, 2022) - Appoints Dr. Kate Broderick as Senior Vice President of Research and Development.

SAN DIEGO, — July 6, 2022 — TriLink BioTechnologies (TriLink), a Maravai LifeSciences company (Maravai) (NASDAQ: MRVI) and a leader in the production of nucleic acids for research, diagnostics and therapeutics applications, today announced that Kate Broderick, Ph.D., has joined the Company as Senior Vice President of Research and Development.  In this newly created role, Kate will have responsibility for leading TriLink’s research and development strategy and scientific direction. S...

(May 24, 2022) - DOD to fund planned manufacturing expansion and to prepare the U.S. for a rapid response to the next pandemic as part of Industrial Base Expansion

SAN DIEGO, — May  24, 2022 — TriLink BioTechnologies (TriLink), a Maravai LifeSciences company (Maravai) (NASDAQ: MRVI), and a leader in the production of nucleic acids for research, diagnostics and therapeutics applications, today announced a Cooperative Agreement with the Army Contracting Command, in coordination with the Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-C...

(October 4, 2021) - EyeGene expected to utilize TriLink’s CleanCap® technology and modified UTP manufactured by TriLink in the production of its EG-COVID mRNA COVID-19 vaccine for clinical trials

SAN DIEGO, October 4, 2021 — TriLink BioTechnologies (“TriLink”), a Maravai LifeSciences company (Nasdaq: MRVI) and a leader in the production of nucleic acids for research, diagnostics and therapeutics applications, announced today that it expects to supply its proprietary CleanCap® ...

(August 3, 2021) - TriLink enables Chula VRC to take its Covid-19 vaccine into a First in Human (FIH) phase 1 clinical trial in Thailand with mRNA manufacturing process development and its proprietary mRNA capping technology, ushering a much-needed vaccine into economically developing countries.

SAN DIEGO — TriLink BioTechnologies (“TriLink”), a Maravai LifeSciences company (Nasdaq: MRVI) and a leader in the production of nucleic acids for research, diagnostics and therapeutics ap...

(March 15, 2021) - New integrated offering will help to meet expected increases in global demand by simplifying and accelerating production of GMP-grade mRNA product for downstream vaccine and therapeutic manufacturing.

SAN DIEGO — Maravai LifeSciences (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, has expanded its contract development and manufacturing organization (CDMO) capabilities at TriLink BioTec...

(August 25, 2020) - Second manufacturing expansion within a year will help meet global demand for research, clinical and GMP grade raw materials as well as research and clinical grade APIs to include mRNA, self-amplifying RNA and plasmid DNA

SAN DIEGO, Calif. — Maravai LifeSciences, a global provider of life science reagents and services to researchers and biotech innovators, is expanding its contract development and manufacturing organization (CDMO) capabilities at TriL...

(April 27, 2020) - SAN DIEGO –TriLink BioTechnologies®, a Maravai LifeSciences company and a leader in the production of nucleic acids for research, diagnostics and therapeutics applications, and Imperial College London, a public research university located in the United Kingdom, announced today that they have entered into a partnership in which TriLink will manufacture self-amplifying RNA (saRNA) for COVID-19 vaccine development. The vaccine development program is led by Professor Robin Shattock, Head of Mucosal Infection and Immunity within the Department of Infectious Disease at ...

(February 11, 2020) - SAN DIEGO – TriLink BioTechnologies®, a Maravai LifeSciences company and a leader in the production of nucleic acids for research, diagnostics and therapeutics applications, announced today the addition of two key executives to its leadership team.

Ray Kaczmarek joins TriLink as senior vice president of GMP operations. Kaczmarek, who has over 20 years of experience in pharmaceutical and biotechnology manufacturing and supply chain operations, most recently served as president of Nitto Avecia Pharma Services, a contract development and manufacturing organization support...

(January 7, 2020) - Advancements Expected to Accelerate Development of mRNA Therapeutics

SAN DIEGO  – TriLink BioTechnologies, a Maravai LifeSciences company and a leader in the production of nucleic acids such as DNA and RNA, announced today that the United States Patent and Trademark Office has issued two new patents to the company. Both patents cover advancements in TriLink’s CleanCap® technology for the co-transcriptional capping of messenger RNAs (mRNAs). Capping is an important step in the production of synthetic mRNA, which is used to develop nucleic acid therapeutics tha...

(November 20, 2019) - SAN DIEGO  – mRNA Day is being celebrated in the City of San Diego following a proclamation in honor of Maravai LifeSciences and the grand opening of its new headquarters in the City. A leader in providing reagents to researchers, biotherapeutics manufacturers and OEM partners worldwide; Maravai invested $40 million into the 105,000 square-foot headquarters located in Sorrento Valley, which features a 50,000 square foot manufacturing facility with five state-of-the-art cleanrooms for TriLink BioTechnologies, a leader in the synthesis of highly modified nucleic acids includi...

(October 14, 2019) - Two New Sets of Barcode Convert Primers are Optimized for Ion Torrent* Sequencers

SAN DIEGO – TriLink BioTechnologies, a Maravai LifeSciences company and leader in oligonucleotide and mRNA synthesis for research, diagnostics and therapeutics, introduces two new primer sets for its CleanTag® kit. The new Ion Torrent Convert barcode primer sets enable small RNA library preparation on the sequencer platform from Thermo Fisher Scientific. TriLink’s CleanTag Small RNA Library Prep Kit has been in use for several years with Illumina* sequencer...

(November 29, 2018) - TriLink BioTechnologies, a Maravai LifeSciences company and a leader in oligonucleotide and mRNA synthesis for research, diagnostics and therapeutics, announced today that the company’s CleanTag® Small RNA Library Prep Kit was the enabling technology in a new study of next-generation sequencing of small RNAs from single cells. The study, Efficient Production of On-Target Reads for Small RNA Sequencing of Single Cells Using Modified Adapters, demonstrates the successful sequencing of small RNA at the single-cell level, a process that had previously proven challenging. The pape...

(October 9, 2018) - Maravai LifeSciences, a leader in providing reagents to researchers, biotherapeutics manufacturers and OEM partners worldwide, today announced that it has hired Christopher Shaffer as senior director of oligonucleotide process development for TriLink BioTechnologies. In this new position, Shaffer will develop and refine processes that improve overall efficiency and will be instrumental when TriLink relocates to a new facility next year. Shaffer will oversee workflows, automation and other elements of testing and manufacturing including scaleup. He will also provide technical support to TriL...

In the News

TriLink BioTechnologies collaborates with Johns Hopkins University to establish a new RNA Innovation Center

(Business Wire: May 13, 2024) - TriLink is collaborating with the Johns Hopkins University to accelerate transformational research in RNA therapeutics and discovery. A new center within the Johns Hopkins Whiting School of Engineering will accelerate research and therapeutic development, leveraging TriLink’s leading RNA synthesis technology.

Vaccine Developers Leverage mRNA and Other Powerful Technologies

(Genetic Engineering and Biotechnology News: May 1, 2024) - Years from now, when we look back on today’s vaccine development scene, we might say it was almost as consequential as the transition from variolation to vaccination. Variolation, an ancient method, involved the use of infectious material from a person with smallpox to inoculate others against the disease. 

What’s in store for mRNA therapeutics in 2024?

(PM360: March 27, 2024) - We’re about to see a seismic shift in mRNA therapeutics as the field erupts with new drugs under investigation. Clinical development projects have grown from just a few dozen before the pandemic to 1,503 programs today, according to clinicaltrials.gov. In 2024, we w...

Ordinarily Extraordinary - Conversations with women in STEM

(Buzzsprout: March 27, 2024) - Dr. Chanfeng Zhao is the VP of R&D Chemistry at TriLink BioTechnologies. She has over 25 years of experience in nucleotide and modified nucleotide chemistry for sequencing and genomics applications. She co-founded MyChem LLC, a company later acquired by TriLink, specializing in ultra-pure synthetic nucleotides. Chanfeng was the CSO and Co-founder of Sequlite Genomic (acquired by Fapon International), a company...

International Rare Disease Day

(Fox5 News San Diego: February 29, 2024) - Dr. Kate Broderick talks about the different kinds of rare disease and some of the most recent advancements in treatment.

The analytics advancements driving mRNA breakthroughs

(manufacturing CHEMIST: February 14, 2024) - mRNA therapeutics are attracting attention because they can be manufactured rapidly to treat previously undruggable diseases. However, this accelerated development — and the ultimate regulatory approval of mRNA drugs — hinges on advanced nucleic acid testing to fully characterise these molecules to ensure their identity, integrity and purity

Driving Breakthroughs in mRNA Therapeutics with Advanced Analytical Techniques

(American Pharmaceutical Review: February 1, 2024) - As the template for all protein synthesis, mRNA serves as the intermediate that allows cells to use genetic information to respond to the dynamicity of life. When applied for therapeutic purposes, mRNA can produce proteins of interest on demand to treat previously undruggable diseases.

While mRNA therapeutics have been around for over five decades,1 this modality gained visibility during th...

Milestone Approval to Steady Stream, Gene Editing Revs Up

(BioPharm International: January 31, 2024) - With the rise of nucleic acid-based therapeutics, such as the mRNA vaccines, biopharma developers are working toward the next big breakthrough in personalized medicines. Over the past couple of years, the industry has seen more intense partnering activity between developers and biotech firms specializing in gene editing technologies. A look at the advances in gene editing technologies illuminates the strides gaine...

2024 pharma predictions: Therapeutic advances, manufacturing tech

(pharma Manufacturing: January 31, 2024) - The coming year will be characterized by seismic shifts, a consequence of 2023's historic highs as well as its economic lows. From the groundbreaking FDA approval of the first CRISPR-based gene therapy for sickle cell disease to the impact of the Inflation Reduction Act on drug pricing negotiations, the industry now stands at the intersection of innovation and adaptation. 

Scrip Asks…What Does 2024 Hold For Biopharma? Part 4: Transformative Technology

(SCRIP Citeline: January 30, 2024) - More than 75 industry executives and experts gazed into the crystal ball and shared with Scrip their predictions around transformative technologies. Perhaps unsurprisingly, AI was the dominant theme – but gene editing, cell therapies and new targeting modalities were also among the highlights.

Innovation Awards 2023: Voting Now Open

(The Medicine Maker: December 11, 2023) -

December is upon us once more – and that means it’s time for The Medicine Maker to showcase the most innovative technologies of the past 12 months. The list is built on nominations received via The Medicine Maker website – but which innovation leads the rest? It’s up to you to decide. Simply peruse the summaries below and then 

The Shadow of COVID-19

(The Medicine Maker: November 27, 2023) -

Medicine’s Hot New Modality, mRNA, Faces Unclear Regulatory Landscape

(BioSpace: October 25, 2023) - While medicines consisting of modified RNA have been decades in the making, it took the pressure of a global pandemic to push the promising technology past hurdles and onto the market. Thanks to a great deal of innovation, mRNA is now a household name and a rapidly expanding industry for the biopharma world beyond COVID-19. Over 250 ...

The Bright Future of mRNA Vaccines

(ID Transmission: October 9, 2023) - Although mRNA technology has been researched for decades, the COVID-19 pandemic provided an excellent example of the incredible potential of mRNA – especially when it comes to combating infectious diseases. The speed and efficiency of the production process is where mRNA vaccines really stand out from traditional vaccines, but they also offer greater precision regarding what cells are producing and how that alte...

Realizing the Promise of mRNA Tech to Revolutionize Global Health

(Today's Clinical Lab: October 3, 2023) - In today’s post-pandemic world, the potential impact of messenger RNA (mRNA) technology extends far beyond vaccines, signaling a paradigm shift in global health. With this versatile tool, public health experts and biopharmaceutical leaders stand poised to gain significant ground in the fight against emerging health threats and conditions.

An Interview with Jason Downing, Sr Product Manager, Trilink BioTechnologies

(American Pharmaceutical Review: October 1, 2023) - Although it is a ubiquitous biological molecule, mRNA is notoriously unstable. As we continue to innovate and explore the possibilities of using mRNA in next-generation vaccines and therapeutics, a key consideration requires addressing the stability issue. Adding a cap to mRNA is analogous to having a bumper on a car. While mRNA caps have many other uses, one of their primary functions is acting as a protective ba...

Pharma Manufacturing announces the 2023 Pharma Innovation Award winners

(pharma Manufacturing: September 26, 2023) - Pharma Manufacturing, an Endeavor Business Media brand, is proud to unveil this year's Pharma Innovation Award winners. The Pharma Innovation Awards are an annual celebration of new technologies and services that help advance product quality, risk reduction, and manufacturing efficiency.

Optimizing mRNA therapeutics

(pharma Manufacturing: August 31, 2023) - The approval and widespread use of messenger RNA (mRNA)-based vaccines for SARS-CoV-2 represented a significant milestone in the use of mRNA as a therapeutic agent. These products reified the incredible potential of in vitro transcribed (IVT) mRNA theoretically capable of producing nearly any functional protein or peptide in the body. mRNA-based therapeutics were first conceptualized more than three decades ago wi...

The Top 25 Companies of San Diego for 2023

(The Business Report: August 28, 2023) - The Business Report is pleased to announce The Top 25 Companies of San Diego for 2023. Characterized by pioneering technology firms, leading research institutions, the world's highest concentration of military assets, and a thriving tourism sector, the San Diego area boasts one of the most vibrant economies nationwide. Known as "America's Finest City," there are a multitude of reasons for San Diego's appeal to bus...

Manufacturing key to overcoming the next pandemic

(Pharmaforum: August 23, 2023) - Ben Hargreaves looks at the way governments are preparing for a future pandemic. One of the key lessons from COVID-19 was ensuring that sufficient manufacturing capacity is readily available, and this is the area where investment and action are taking place.

At Least 6 Companies Working on COVID Vaccines in San Diego

(10 News San Diego: June 24, 2020) - At least six companies are working on COVID-19 vaccine candidates in San Diego, all within a 1.5-mile radius of where the I-5 and I-805 split. Locally, the farthest along appears to be Inovio Pharmaceuticals, which plans to launch a Phase 2 trial next month, potentially with a simultaneous Phase 3 trial. A Phase 3 trial is the final step in vaccine testing, with thousands of participants. The company is developing...

Coronavirus: Human Trial of New Vaccine Begins in UK

(BBC News: June 24, 2020) - Volunteers have begun being immunised with a new UK coronavirus vaccine. About 300 people will have the vaccine over the coming weeks, as part of a trial led by Prof Robin Shattock and his colleagues, at Imperial College London. Tests in animals suggest the vaccine is safe and triggers an effective immune response. Experts at Oxford University have already started human trials. The trials are among many across the...

mRNA Day: TriLink, Maravai Look to RNA, Oligonucleotides, and San Diego for Growth

(Genetic Engineering & Biotechnology News: December 20, 2019) - A San Diego manufacturer of highly-modified nucleic acids and its parent company have concluded that development of RNA- and oligonucleotide-based therapeutics—as well as the region’s biopharma cluster—will both grow strongly enough in the near future to justify the companies’ recent $50-million investment in relocation and expansion within the city...

RNA Epitranscriptome: Role of the 5’ Cap

(Genetic Engineering & Biotechnology News: May 1, 2019) - Epigenetic modification of RNA, the RNA analog of the DNA epigenome, has been observed for over 40 years and is known as the epitranscriptome. Messenger RNAs (mRNAs) in particular are post-transcriptionally modified, obtaining base modifications as well as 2ʹ methylation of sugars near the 5ʹ cap. Cap modifications identify the mRNA as self rather than foreign, and modulate stability, translation, decappin...

Address Manufacturing and Look Beyond Cancer, Panel Advises Cell and Gene Therapy Companies

(Genetic Engineering & Biotechnology News: March 22, 2019) - The ability of cell and gene therapy companies to raise capital this year will hinge on their ability to address the manufacturing of their products as well as address medical needs beyond cancer, a panel of three investors and an industry executive agreed yesterday...

Contact

CG Life

Email: [email protected]
Phone: 847-702-8099